Quick Answer
Arcturus Therapeutics Holdings Inc. reported Diluted EPS of $2.40 per share (loss) for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.40 | +20.0% |
| 2024 | -$3.00 | -167.9% |
| 2023 | -$1.12 | -420.0% |
| 2022 | $0.35 | +104.5% |
| 2021 | -$7.74 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.49 | -88.5% | -44.1% |
| June 30, 2025 | -$0.34 | +46.9% | +34.6% |
| March 31, 2025 | -$0.52 | +48.0% | -100.0% |
| September 30, 2024 | -$0.26 | +57.4% | +59.4% |
| June 30, 2024 | -$0.64 | +67.7% | +36.0% |
| March 31, 2024 | -$1.00 | -153.5% | -63.9% |
| September 30, 2023 | -$0.61 | +54.1% | +69.2% |
| June 30, 2023 | -$1.98 | -141.5% | -205.9% |
- Arcturus Therapeutics Holdings Inc. showed an increase of +20.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Arcturus Therapeutics Holdings Inc.’s diluted eps has grown by 69.0% (from $7.74 per share (loss) to $2.40 per share (loss)).
- The most recent figure is from Arcturus Therapeutics Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: